Volume 3.07 | Feb 24

Human Immunology News 3.07 February 24, 2015
Human Immunology News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  HIN on Twitter
New HPV Vaccine Shows Promise to Dramatically Reduce Cervical Cancer
A multinational study on a diverse group of women showed that a new nine-valent human papillomavirus (HPV) vaccine prevents infections and disease associated with the vaccine types. [Press release from the University of Alabama at Birmingham discussing an online publication in the New England Journal of Medicine]
Press Release | Video | Abstract
Complimentary Wallchart:  Human Hematopoietic Progenitors.  Request Your Copy Today.
PUBLICATIONS (Ranked by impact factor of the journal)
An Epigenome-Wide Association Study of Total Serum Immunoglobulin E Concentration
Researchers showed replicated associations between immunoglobulin E and low methylation at 36 loci. Genes annotated to these loci encode known eosinophil products and also implicate phospholipid inflammatory mediators, specific transcription factors and mitochondrial proteins. [Nature] Abstract | Press Release

Regulatory T Cells Produce Profibrotic Cytokines in the Skin of Patients with Systemic Sclerosis
Investigators determined whether regulatory T cells in the blood and skin of patients with systemic sclerosis acquired abnormal production of effector cytokines. [J Allergy Clin Immunol] Abstract

Initial Viral Load Determines the Magnitude of the Human CD8 T Cell Response to Yellow Fever Vaccination
The relationship between antigen load and the magnitude of the CD8 T-cell response is not well-described in a human immune response. Investigators address this issue by quantifying viral load and the CD8 T-cell response in a cohort of 80 individuals immunized with the live attenuated yellow fever vaccine by sampling peripheral blood at various time points. [Proc Natl Acad Sci USA] Abstract

Tumor Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
The authors evaluated the anti-tumor activity of adoptively transferred human tumor infiltrating lymphocytes genetically engineered to secrete single-chain interleukin-12 selectively at the tumor site. [Clin Cancer Res] Abstract

Dynamic Co-evolution of Host and Pathogen: HCMV Downregulates the Prevalent Allele MICA*008 to Escape Elimination by NK Cells
A particular highly prevalent MICA allele, MICA*008, is considered to be an human cytomegalovirus (HCMV)-resistant “escape variant” that confers advantage to human natural killer (NK) cells in recognizing infected cells. However, researchers showed that HCMV uses its viral glycoprotein US9 to specifically target MICA*008 and thus escapes NKG2D attack. [Cell Rep] Full Article | Graphical Abstract

STAT5 Phosphorylation in T Cell Subsets from Septic Patients in Response to Recombinant Human Interleukin-7: A Pilot Study
Researchers assessed CD4+ lymphocyte responsiveness to rhIL-7 in septic shock patients ex vivo. The MFI of pSTAT5, a key signaling molecule for IL-7, was measured by flow cytometry in CD4+FOXP3 and CD4+FOXP3+ lymphocytes after whole-blood incubation with increasing doses of rhIL-7. [J Leukoc Biol] Abstract

Guanine-Modified Inhibitory Oligonucleotides Efficiently Impair TLR7- and TLR9-Mediated Immune Responses of Human Immune Cells
Researchers evaluated the inhibitory/therapeutic potential of a set of G-modified inhibitory oligonucleotides (INH-ODNs) on human immune cells. They report that G-modified INH-ODNs efficiently inhibited the release of IFN-α by PBMC stimulated either with the TLR7-ligand oligoribonucleotide 22075 or the TLR9-ligand CpG-ODN 2216. [PLoS One] Full Article

Leishmania donovani Skews the CD56+ Natural Killer T Cell Response during Human Visceral Leishmaniasis
Scientists sought to understand the categorical function of CD4+CD56+ and CD8+CD56+ natural killer T cells in human visceral leishmaniasis. [Cytokine] Abstract

Subscribe to our sister publications:
Immunology of Infectious Disease News and Immune Regulation News

Learn how to complete, submit and review BMT registry forms locally. Join the Webinar.
Combination Immunotherapies for Type 1 Diabetes Mellitus
The authors summarize the available data about combination immunotherapies in type 1 diabetes mellitus, particularly addressing their clinical importance. [Nat Rev Endocrinol] Abstract

Role of Ion Channels in Regulating Ca2+ Homeostasis during the Interplay between Immune and Cancer Cells
The authors discuss the implication of ion channels in regulation of Ca2+ homeostasis during the crosstalk between immune and cancer cell as well as their role in cancer progression. [Cell Death Dis] Full Article

Visit our reviews page to see a complete list of reviews in the human immunology research field.
Bavarian Nordic Announces Updated Overall Survival Data from Combination Immunotherapy Data of PROSTVAC plus Ipilimumab
Bavarian Nordic A/S announced that updated overall survival data from an NCI sponsored combination study of Bavarian Nordic’s active prostate cancer immunotherapy candidate PROSTVAC and ipilimumab, an immune checkpoint inhibitor will be presented. [Press release from Bavarian Nordic A/S discussing research to be presented at the 2015 Genitourinary Cancers Symposium, Orlando] Press Release | Abstract

Celsion Corporation Presents Clinical and Preclinical Data for GEN-1 IL-12 Immunotherapy in Ovarian Cancer
Celsion Corporation presented clinical and preclinical data demonstrating the safety, biological activity and clinical benefits of GEN-1, its DNA-based immunotherapy, as a single agent in advanced platinum-resistant and recurrent ovarian cancer patients. [Press release from Celsion Corporation discussing research presented at the Molecular Medicine TRI-Conference, San Francisco] Press Release | Presentation

Breastfeeding, Other Factors Help Shape Immune System Early in Life
Striking findings from a series of studies further advance the so-called hygiene hypothesis theory that early childhood exposure to microorganisms affects the immune system’s development and onset of allergies. [Press release from Henry Ford Health System discussing research presented at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, Houston] Press Release

ADMA Biologics Announces Positive Data on Primary and Secondary Endpoints from Its Pivotal Phase III Clinical Trial for RI-002
ADMA Biologics, Inc. announced positive results on the primary and secondary endpoint evaluations from its pivotal Phase III trial for RI-002 in primary immune deficiency disease in a poster presentation. [Press release from ADMA Biologics, Inc. discussing research presented at the 2015 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting, Houston] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
Rigel and Bristol-Myers Squibb Announce Research and Development Collaboration for TGF Beta Receptor Kinase Inhibitors for Use in Immuno-Oncology Related Indications
Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel’s extensive portfolio of small molecule TGF beta receptor kinase inhibitors. [Bristol-Myers Squibb Company] Press Release

Agilvax Announces Strategic Collaboration with Humabs BioMed SA to Develop Targeted Vaccines and Immunotherapies
Agilvax, Inc. announced a collaboration with Switzerland based Humabs BioMed that will contribute to the rapid advancement of Agilvax’s ever expanding vaccine and immunotherapy pipeline. [Agilvax, Inc.] Press Release

T-Cell Therapy Clinical Trial Now Offered to Cancer Patients at C.S. Mott Children’s Hospital
A clinical trial using T-cell therapy that uses the patients’ own immune cells to hunt down cancer cells is now being offered at the University of Michigan’s C.S. Mott Children’s Hospital. [University of Michigan Health System] Press Release

Celldex’s Rindopepimut (Rintega®) Receives FDA Breakthrough Therapy Designation for the Treatment of Adult Patients with EGFRvIII-Positive Glioblastoma
Celldex Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Rintega® Breakthrough Therapy Designation for the treatment of adult patients with EGFRvIII-positive glioblastoma. [Celldex Therapeutics, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2015 Microbiology and Immunology Conference (MIC 2015)
March 18-20, 2015
Suzhou, China

NEW Keystone Symposium – Innate Immunity and Determinants of Microbial Pathogenesis
April 19-24, 2015
Olympic Valley, United States

Visit our events page to see a complete list of events in the human immunology community.
NEW Postdoctoral Position – Immunology (Oregon Health & Science University)

Scientist – Recombinant Molecules and Antibodies (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Faculty Position – Immunology (The Lowance Center for Human Immunology at Emory University)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Director – Vector Production (Sangamo BioSciences, Inc.)

Research Associate – Innate/Adaptive Immune Components in the Microenvironment of Basal-Like Breast Cancers (King’s College London)

Postdoctoral Researcher – Cancer Immunology and Immunotherapy (United Arab Emirates University)

Manufacturing Scientists – Chimeric Antigen Receptor T-Cell Therapy (Autolus)

Postdoctoral Position – Cancer-Related Inflammation (Institute of Human Genetics)

Research Scientist – Cancer Immunotherapy (iTeos Therapeutics)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Human Immunology News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Human Immunology News: Archives | Events | Contact Us